Diploma PLC (LON:DPLM) Insider Sells £1,215,375.84 in Stock

Diploma PLC (LON:DPLM) insider Johnny Thomson sold 26,794 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of GBX 4,536 ($56.86), for a total transaction of £1,215,375.84 ($1,523,600.15).

Diploma Stock Performance

LON:DPLM opened at GBX 4,466 ($55.99) on Friday. The company has a market capitalization of £5.99 billion, a P/E ratio of 5,179.07, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. Diploma PLC has a twelve month low of GBX 3,200 ($40.12) and a twelve month high of GBX 4,653 ($58.33). The company has a current ratio of 2.27, a quick ratio of 0.80 and a debt-to-equity ratio of 45.69. The firm has a 50-day moving average price of GBX 4,384.83 and a two-hundred day moving average price of GBX 4,265.19.

Diploma Increases Dividend

The company also recently declared a dividend, which will be paid on Friday, January 31st. Stockholders of record on Thursday, January 16th will be issued a dividend of GBX 42 ($0.53) per share. The ex-dividend date of this dividend is Thursday, January 16th. This is an increase from Diploma’s previous dividend of $17.30. This represents a dividend yield of 0.93%. Diploma’s payout ratio is 6,627.91%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DPLM. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 5,100 ($63.93) price target on shares of Diploma in a research note on Friday. Shore Capital downgraded shares of Diploma to a “hold” rating in a report on Tuesday.

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.